In the global medicinal chemistry agreement a dedicated team of chemists from Evotec supports all of Roche’s European and US research sites in the design and synthesis of high quality compounds for lead finding and optimization programs.
In the medicinal chemistry oncology collaboration, both companies aim to identify and develop a clinical lead candidate for a priority target within Roche’s oncology research.
“These significant research programs announced today are of particular importance for Evotec. They emphasize our world leading expertise in medicinal chemistry and the continued trust of our partner Roche. We look forward to continuing to work closely with scientists at Roche for a number of years,” said Dr Mark Ashton, executive vice president of business development services at Evotec.